NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Price Target & More

$7.38 +0.34 (+4.83 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$7.04
Today's Range$6.89 - $7.38
52-Week Range$6.15 - $11.34
Volume8,486 shs
Average Volume26,259 shs
Market Capitalization$106.59 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ORMP
CUSIPN/A
Phone011-972-2-566-0001

Debt

Debt-to-Equity RatioN/A
Current Ratio4.48%
Quick Ratio4.48%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.46 million
Price / Sales43.32
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book5.20

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-10,480,000.00
Net Margins-165.01%
Return on Equity-49.12%
Return on Assets-25.53%

Miscellaneous

Employees14
Outstanding Shares14,440,000

How to Become a New Pot Stock Millionaire

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 equities research analysts have issued 12-month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $20.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $22.50 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Kevin L. Rakin, Chairman of the Board, Independent Director (Age 57)
  • Nadav Kidron, President, Chief Executive Officer, Director (Age 43)
  • Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
  • Joshua Hexter, Chief Operating Officer, Vice President - Business Development (Age 46)
  • Miriam Kidron Ph.D., Chief Scientific Officer, Director (Age 76)
  • Ronald Edward Law, Chief Strategy Officer (Age 64)
  • Aviad Friedman, Independent Director (Age 45)
  • Xiaopeng Li, Independent Director (Age 33)
  • Leonard Sank, Independent Director (Age 52)
  • David Slager, Independent Director (Age 44)

Has Oramed Pharmaceuticals been receiving favorable news coverage?

Press coverage about ORMP stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a news impact score of 0.23 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 44.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $7.38.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $106.59 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oramed Pharmaceuticals (NASDAQ:ORMP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Oramed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 204.88%. The high price target for ORMP is $25.00 and the low price target for ORMP is $20.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50$22.50$25.00
Price Target Upside: 204.88% upside158.62% upside158.62% upside149.50% upside

Oramed Pharmaceuticals (NASDAQ:ORMP) Consensus Price Target History

Price Target History for Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018B. RileyReiterated RatingBuy$20.00MediumView Rating Details
11/22/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00N/AView Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00N/AView Rating Details
5/18/2016AegisReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Oramed Pharmaceuticals (NASDAQ:ORMP) Earnings History and Estimates Chart

Earnings by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) Earnings Estimates

2018 EPS Consensus Estimate: ($1.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.33)($0.33)($0.33)

Oramed Pharmaceuticals (NASDAQ ORMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018        
1/11/2018Q1 2018($0.24)($0.18)$0.62 million$0.61 millionViewN/AView Earnings Details
11/29/2017Q4 2017($0.20)$4.29 millionViewN/AView Earnings Details
7/6/2017Q3 2017($0.27)($0.15)$0.61 million$0.62 millionViewN/AView Earnings Details
4/5/2017Q2 2017($0.19)($0.24)$0.60 million$0.61 millionViewN/AView Earnings Details
1/11/2017Q1 2017($0.20)$0.61 millionViewN/AView Earnings Details
11/25/2016Q4 2016($0.37)$0.19 million($0.93) millionViewN/AView Earnings Details
7/6/2016Q3 2016($0.19)($0.15)$0.20 million$0.16 millionViewN/AView Earnings Details
4/6/2016Q2 2016($0.19)($0.14)$0.20 million$0.13 millionViewN/AView Earnings Details
1/13/2016Q1 2016($0.19)($0.21)ViewN/AView Earnings Details
11/25/2015Q4 2015($0.17)($0.19)ViewN/AView Earnings Details
7/1/2015Q3 2015($0.21)($0.15)ViewN/AView Earnings Details
4/3/2015Q2 2015($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Oramed Pharmaceuticals (NASDAQ:ORMP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 2.62%
Insider Trading History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Institutional Ownership by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2017Xiaopeng LiDirectorBuy89,636$8.50$761,906.00206,350View SEC Filing  
4/19/2017Miriam KidronInsiderSell52,814$6.33$334,312.62View SEC Filing  
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00957,448View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00142,450View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.0022,896View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.0023,596View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines

Source:
DateHeadline
Oramed Pharmaceuticals (ORMP) Cut to Sell at ValuEngineOramed Pharmaceuticals (ORMP) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 20 at 12:24 AM
FY2018 Earnings Estimate for Oramed Pharmaceuticals Inc. Issued By B. Riley (ORMP)FY2018 Earnings Estimate for Oramed Pharmaceuticals Inc. Issued By B. Riley (ORMP)
www.americanbankingnews.com - April 19 at 7:18 AM
Form 4 ORAMED PHARMACEUTICALS For: Apr 08 Filed by: Hexter JoshuaForm 4 ORAMED PHARMACEUTICALS For: Apr 08 Filed by: Hexter Joshua
www.streetinsider.com - April 11 at 8:31 AM
Oramed Pharmaceuticals (ORMP) Raised to Hold at ValuEngineOramed Pharmaceuticals (ORMP) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 12:32 AM
Oramed Pharmaceuticals (ORMP) Given "Buy" Rating at B. RileyOramed Pharmaceuticals (ORMP) Given "Buy" Rating at B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM
Oramed to Present at HC Wainwright Annual Global Life Sciences ConferenceOramed to Present at HC Wainwright Annual Global Life Sciences Conference
www.prnewswire.com - March 27 at 5:13 PM
Oramed to Present at H.C. Wainwright Annual Global Life Sciences ConferenceOramed to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 27 at 8:28 AM
Oramed to Present at Oppenheimers Annual Healthcare Conference - PR Newswire (press release)Oramed to Present at Oppenheimer's Annual Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:21 AM
Oramed to Present at Oppenheimers Annual Healthcare ConferenceOramed to Present at Oppenheimer's Annual Healthcare Conference
finance.yahoo.com - March 15 at 6:11 PM
Oramed Adds Two New Members to its Scientific Advisory Board - PR Newswire (press release)Oramed Adds Two New Members to its Scientific Advisory Board - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:15 AM
Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension - PR Newswire (press release)Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension - PR Newswire (press release)
www.prnewswire.com - February 22 at 8:22 AM
Oramed Pharmaceuticals (ORMP) Rating Lowered to Sell at ValuEngineOramed Pharmaceuticals (ORMP) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - February 21 at 12:56 AM
Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and HypertensionOramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension
finance.yahoo.com - February 20 at 5:46 PM
Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - February 10 at 12:44 PM
Oramed to Present at BIO CEO Investor Conference - PR Newswire (press release)Oramed to Present at BIO CEO Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 8 at 8:11 AM
Oramed to Present at BIO CEO Investor ConferenceOramed to Present at BIO CEO Investor Conference
finance.yahoo.com - February 6 at 9:33 AM
FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment ResearchFY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research
www.americanbankingnews.com - February 1 at 12:32 PM
Oramed Pharmaceuticals CEO Issues Letter to ShareholdersOramed Pharmaceuticals' CEO Issues Letter to Shareholders
www.bizjournals.com - January 19 at 11:48 AM
Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018
finance.yahoo.com - January 19 at 11:48 AM
Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.s FY2018 Earnings (ORMP)Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.'s FY2018 Earnings (ORMP)
www.americanbankingnews.com - January 18 at 2:58 PM
Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular AtrophyBlog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy
finance.yahoo.com - January 18 at 11:16 AM
Oramed Pharmaceuticals (ORMP) Rating Increased to Hold at ValuEngineOramed Pharmaceuticals (ORMP) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 2:20 PM
Oramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to HoldOramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - December 23 at 4:14 PM
Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per ShareOramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - December 13 at 10:26 AM
Oramed Pharmaceuticals (ORMP) "Buy" Rating Reaffirmed at B. RileyOramed Pharmaceuticals' (ORMP) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - December 11 at 10:10 PM
B.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.comB.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.com
www.streetinsider.com - December 11 at 4:44 PM
ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to SellValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell
www.americanbankingnews.com - December 5 at 10:12 PM
Heres Why And How Oramed Pharmaceuticals Is Going After NASHHere's Why And How Oramed Pharmaceuticals Is Going After NASH
www.benzinga.com - November 28 at 4:31 PM
Oramed Pharmaceuticals (ORMP) "Buy" Rating Reiterated at HC WainwrightOramed Pharmaceuticals' (ORMP) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 22 at 8:40 AM
 Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00 Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - November 20 at 10:32 AM
Reviewing Oramed Pharmaceuticals (ORMP) and Its PeersReviewing Oramed Pharmaceuticals (ORMP) and Its Peers
www.americanbankingnews.com - November 19 at 9:26 PM
Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its RivalsCritical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals
www.americanbankingnews.com - November 19 at 3:30 PM
FDA Nod For AZNs Asthma Drug, Genmab Revises Outlook, NBY Disappoints - NasdaqFDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints - Nasdaq
www.nasdaq.com - November 15 at 7:10 AM
Oramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.comOramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.com
www.streetinsider.com - November 15 at 7:10 AM
Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin CapsuleOramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
finance.yahoo.com - November 15 at 7:10 AM
Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral ProteinsOramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins
www.streetinsider.com - November 2 at 7:22 AM
Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.comOramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.com
www.streetinsider.com - November 1 at 7:18 AM
Oramed Granted Broad Composition of Matter Patent in Europe for Oral ProteinsOramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
finance.yahoo.com - November 1 at 7:18 AM
Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - October 30 at 4:02 AM
Oramed to Present at the Diabetes Technology MeetingOramed to Present at the Diabetes Technology Meeting
finance.yahoo.com - October 25 at 8:42 AM
Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its ScientistsOramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its Scientists
www.streetinsider.com - October 18 at 1:50 AM
Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.comOramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.com
www.streetinsider.com - October 17 at 3:45 PM
Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed ScientistsEndocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists
finance.yahoo.com - October 17 at 3:45 PM
Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)
www.americanbankingnews.com - October 7 at 6:28 PM
HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)
www.americanbankingnews.com - October 5 at 3:38 PM
Oramed to Present at the Disruptive Growth Showcase ConferenceOramed to Present at the Disruptive Growth Showcase Conference
finance.yahoo.com - October 2 at 9:19 PM
Oramed Now Has a Clear Path to Market With Oral InsulinOramed Now Has a Clear Path to Market With Oral Insulin
finance.yahoo.com - September 23 at 9:12 AM
Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - September 12 at 2:26 AM
Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801
www.streetinsider.com - September 6 at 7:16 AM
Oramed Announces Successful Meeting with FDA for Oral InsulinOramed Announces Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM

SEC Filings

Oramed Pharmaceuticals (NASDAQ:ORMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oramed Pharmaceuticals (NASDAQ:ORMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oramed Pharmaceuticals (NASDAQ ORMP) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.